长春高新(000661.SZ)：注射用GenSci140境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial application of GenSci140, a novel targeted antibody-drug conjugate aimed at treating locally advanced or metastatic solid tumors [1] Group 1 - The clinical trial approval pertains to GenSci140, which targets the folate receptor alpha (FRα) [1] - GenSci140 is classified as a Class 1 biological product for therapeutic use [1] - The drug is developed independently by Jinsai Pharmaceutical [1]